OraSure Technologies (NASDAQ:OSUR) Announces Earnings Results, Beats Estimates By $0.03 EPS

OraSure Technologies (NASDAQ:OSUR) posted its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03, FiscalAI reports. OraSure Technologies had a negative return on equity of 10.81% and a negative net margin of 36.84%.The business had revenue of $27.09 million during the quarter, compared to analysts’ expectations of $28.96 million. OraSure Technologies updated its Q4 2025 guidance to EPS.

OraSure Technologies Trading Up 0.2%

OraSure Technologies stock traded up $0.01 during mid-day trading on Friday, hitting $2.41. The company’s stock had a trading volume of 232,844 shares, compared to its average volume of 699,883. The stock’s fifty day moving average is $3.09 and its two-hundred day moving average is $2.99. The firm has a market capitalization of $175.89 million, a PE ratio of -3.59 and a beta of 0.54. OraSure Technologies has a 1 year low of $2.30 and a 1 year high of $4.36.

Institutional Trading of OraSure Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. boosted its stake in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 8,133 shares during the period. Prudential Financial Inc. acquired a new position in shares of OraSure Technologies in the 2nd quarter worth approximately $31,000. Amundi purchased a new position in shares of OraSure Technologies during the 1st quarter worth approximately $47,000. Jane Street Group LLC increased its holdings in OraSure Technologies by 14.1% in the 2nd quarter. Jane Street Group LLC now owns 157,871 shares of the medical instruments supplier’s stock valued at $474,000 after purchasing an additional 19,494 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in OraSure Technologies by 7.2% in the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after purchasing an additional 27,310 shares during the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OraSure Technologies currently has an average rating of “Reduce” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.